Alpha Tau and Tolmar Partner to Expand Alpha DaRT Therapy into U.S. Prostate Cancer Market — Alpha Tau Medical Ltd.

Event summary

Alpha Tau and Tolmar have entered a strategic collaboration to commercialize Alpha DaRT therapy for prostate cancer in the U.S., with Tolmar investing $35M upfront ($20M equity infusion at $11.99 per share and $15M for U.S. manufacturing).
Tolmar gains exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer, backed by up to $161.5M in clinical, regulatory, and commercial milestones.
Alpha Tau will manufacture Alpha DaRT for Tolmar, selling the product at 60% of the onward net sales price, subject to adjustments.
The collaboration leverages Tolmar’s commercial expertise in urology and oncology, while Alpha Tau focuses on clinical development and manufacturing.

The big picture

This collaboration marks a significant step in expanding Alpha DaRT’s reach into the U.S. prostate cancer market, leveraging Tolmar’s commercial expertise. The deal reflects a broader trend of biotech companies partnering with specialty pharma firms to accelerate market entry and scale. With prostate cancer being a high-prevalence indication, the success of this partnership could set a precedent for similar collaborations in oncology.

What we're watching

Clinical Progress: The pace at which Alpha DaRT advances through U.S. clinical trials will determine the timeline for regulatory approval and commercial launch.
Market Penetration: Whether Tolmar can effectively position Alpha DaRT as a competitive alternative to existing prostate cancer treatments will shape its market adoption.
Execution Risk: Alpha Tau’s ability to scale manufacturing and meet Tolmar’s commercial demands will be critical to the partnership’s success.